On Friday, MGM Resorts International (NYSE:MGM)’s shares inclined 1.21% to $20.97.
MGM Resorts International (MGM) employee volunteers build a house from the ground up, and hand over the keys to an elated single mother and her children. Tens of millions of dollars are spent conducting business with minority- and women-owned enterprises, supporting the company’s planned objectives and commitment to diversity. MGM Resorts and NRG Renew partner to install one of the nation’s largest rooftop solar arrays at Mandalay Bay Resort and Casino, stretching a massive 20 acres.
From introducing the gaming industry’s first formal diversity and inclusion initiative in 2000 to building the world’s largest LEED Gold-certified “green” complex in CityCenter, to marshaling its employees to donate more than 1.6 million pounds of food last year, CSR is foundational to MGM Resorts’ culture.
MGM Resorts International, through its auxiliaries, owns and/or operates casino resorts. It operates through two segments, Wholly Owned Domestic Resorts and MGM China. The company’s casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. Its casino operations comprise slots, table games, and race and sports book wagering. The company operates 15 wholly owned resorts in the United States; and the MGM Macau resort and casino in China, in addition to develops a gaming resort in Cotai, Macau. It also owns Shadow Creek golf course, Primm Valley golf club, and Fallen Oak golf course.
Bristol-Myers Squibb Co (NYSE:BMY)’s shares gained 0.83% to $59.24.
Bristol-Myers Squibb Company (BMY) declared that the European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union, and marks the first time these patients with genotype 3 HCV have a once-daily, all-oral treatment regimen of this shorter duration.
In August 2014, Daklinza was approved by the European Commission for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults. The original label comprised of treatment of patients with genotype 3 (with or without compensated cirrhosis and/or treatment-practiced) with Daklinza and sofosbuvir and ribavirin, for 24 weeks. The updated label, which removes the requirement for ribavirin and reduces treatment duration to 12 weeks for patients without cirrhosis, is based on data presented to the European Medicines Agency and the Committee for Medicinal Products for Human Use from the ALLY-3 clinical trial. The updated treatment regimen for patients with cirrhosis is for Daklinza plus sofosbuvir with the optional use of ribavirin, which may be added based on clinical assessment of the patient. The treatment duration for these patients has not changed.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The companys products comprise Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders.
At the end of Friday’s trade, Office Depot Inc (NASDAQ:ODP)‘s shares surged 0.13% to $7.45.
Office Depot, Inc. (ODP), a leading global provider of office products, services and solutions and parent company of Office Depot and OfficeMax, found that small- and medium-sized businesses (SMBs) cite office supplies as their top investment for the second half of 2015. SMB owners believe office supplies fuel business operations and produce feelings of productivity and control, assisting them “gear up for great.”
Despite technology’s prevalence in the work place, 42% of SMBs say that paper is their favorite office gear, while another 26% say pens are their front runner. However, technology earns a nod, with 39% preferring ink and toner and 20% listing computers (desktops and laptops) as their fourth most desired supply.
Office Depot, Inc., together with its auxiliaries, supplies office products and services. The company’s North American Retail division sells an assortment of merchandise, counting office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores. Its North American Business Solutions division sells branded office supplies, technology products, cleaning and breakroom supplies, office furniture, and other solutions, in addition to copy and print services to small, medium, and large-sized businesses through a sales force, catalogs, telesales, and Internet sites.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
